Yan Noi's new antibiotic cefiderocol treatment hospital obtained pneumonia adult patients 3 study reached the main endpoint

recently, Japan's Shionogicompany(http:// announcedthat it had developed a new antibiotic, cefiderocol, to reach the main endpoint of theexperimental(http://in the phase 3 study of APEKS-NP in adult patients treating acquired pneumonia (NP) in the hospital, Yanye has submitted aapplication to theFDA(http://for thenew drug(http:// which is expected to be approved in NovemberAbout cefiderocol
cefiderocol is a new iron carrier cephalosporin antibiotic drug (http:// cefiderocol has a unique mechanism that not only allows the drug to pass through the cell membranes of Gram-negative bacteria pathogens, including multidrug-resistant (MDR) strains, but also enables cefiderocol to reach a high concentration within the cell perimeter, bind smoothly to the receptors, and inhibit the cell wall synthetic (http:// cefiderocol can also fight a variety of beta-lactamase classes previous studies have shown that cefiderocol has good drug efficacy in vitro against a variety of gram-negative bacteria, including anti-carbon ilostria 　　The data released this comes from a double-blind, random 3-phase non-performance test results showed that cefiderocol achieved a non-effect severance in the 14-day all-cause mortality rate in the patient group of improved intent therapy (MITT) compared to the active control group who received high doses of meropenem treatment - 12.4% in the cefiderocol group and 11.6% in the control group in the microbiology-assessable patient population, the data was 12.4% (cefiderocol) to 13% (control group) cefiderocol also reached several key secondary endpoints of the experiment